Skip to main content
INVE $2.65 +0.00%
INVE logo

INVE · Identiv, Inc.

Track INVE — free
$2.65 +0.00 (+0.00%) At close · Aug 14
Market Cap
$64.22M
Shares
24.24M
All earnings calls

Earnings call · FY2024 Q4

Identiv, Inc. Q4 FY2024 Earnings Call

Identiv, Inc. Q4 FY2024 Earnings Call

Concluded Mar 5, 2025
Mar 5, 2025 32 turns
Period
FY2024 Q4
Runtime
Sources
3 artifacts

Executive readout · one minute

Call research workspace

Read the call alongside every captured source. Audio, transcript, slides and SEC filings stay in one workspace.

Singapore-to-Thailand production transition 48 EBITDA breakeven and 2025 outlook 21 Novanta partnership in healthcare 21 PAT growth strategy execution 20 Gross margin recovery 13 New product development and design wins 11

Management tone

Positive

Net tone +15 · moderate hedging

Grounding quotes
  • “Q4 outperformance versus this revenue guidance was primarily due to one of our customers accelerating their delivery schedule from Q1 of 2025 to Q4 as a precaution ahead of transferring their production to Thailand.”
  • “We haven't formally established a timeline for EBITDA breakeven, so we aren't setting a two-year target for that.”
  • “I don't think we can guide too much on that, but I will say we're excited about the projects that are coming our way. They largely will take some development in 2025, but we expect more of the growth associated with them towards 2026.”
  • “Fourth quarter GAAP and non-GAAP gross margin was negative 14.9% and negative 5.2%, respectively, compared to GAAP and non-GAAP positive gross margin of 16.2% and 19.5%, respectively, in Q4 2023.”

Research coverage

3 live sources

Switch sources without leaving this page or losing your listening position.

Revenue · derived Q4 $6.70M
Gross margin · derived Q4 -14.9% -121.7 pp YoY
Net income · derived Q4 -$355,000

Research materials

Open the source you need; every reader stays inside this workspace.

Full-screen source Call document